Your session is about to expire
What is Rayaldee
Approved as Treatment by the FDA
Calcifediol, also known as Rayaldee, is approved by the FDA for 6 uses including Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease, Stage 3 (Moderate) .Effectiveness
When to interrupt dosage
The quantity of Rayaldee is dependent upon the diagnosed disorder, including Chronic Kidney Disease, Stage 3 (Moderate), Stage 4 Chronic Kidney Disease and Hyperparathyroidism, Secondary. The dosage varies, contingent upon the procedure of delivery (e.g. Capsule - Oral or Oral) featured in the table beneath.Warnings
There are 20 known major drug interactions with Rayaldee.Rayaldee Novel Uses: Which Conditions Have a Clinical Trial Featuring Rayaldee?
Currently, there are 10 active studies evaluating the potential of Rayaldee to ameliorate Chronic Kidney Disease Stage 3 (Moderate), Secondary Hyperparathyroidism and Vitamin D Deficiency (10 ng/mL to 30 ng/mL).Rayaldee Reviews: What are patients saying about Rayaldee?
Patient Q&A Section about rayaldee
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Rayaldee vitamin D?
"RAYALDEE is a treatment for hyperparathyroidism that comes as a result of chronic kidney disease. It is for stage 3 or 4 adult patients who have a serum total 25-hydroxyvitamin D level that is less than 30 ng/mL."
What is Rayaldee used for?
"Rayaldee is an extended-release capsule taken by mouth that is prescribed to treat adults with secondary hyperparathyroidism, stage 3 or 4 chronic kidney disease, and low vitamin d levels."
Is there a generic for Rayaldee?
"Currently, there is no drug in the United States that is the same as Rayaldee. However, there are fake versions of Rayaldee being sold online by unlicensed pharmacies. These drugs may not be safe, as they are not regulated."
Who manufactures Rayaldee?
"OPKO, a company based in Miami, announced today that the FDA has approved their drug Rayaldee for chronic kidney disease. This approval comes only three months after OPKO received a complete response letter from the FDA, due to concerns that the FDA had about the plant where the drug was being produced."